Pandemic Report: Vaccine immune response | antibodies study | Immunocompromised

A look at vaccine immune response

ST. LOUIS, MO—Researchers at Washington University School of Medicine in St. Louis have found evidence that the immune response to COVID-19 vaccines is both strong and long-lasting. The research involved extracting cells from people who received the Pfizer vaccine at three-, four-, five- and seven-week intervals.

COVID-19 antibodies study

DETROIT, MI—Beaumont Health, Southeast Michigan’s largest health care system, has launched a two-year study designed to better understand how a person develops vaccine-induced COVID-19 antibodies and how long those antibodies last.

Post-infection treatment for COVID

MANHATTAN, KANSAS—Kansas State University researchers have published a study that demonstrates successful post-infection treatment for SARS-CoV-2. College of Veterinary Medicine researchers found that animal models infected with SARS-CoV-2 and treated with an inhibitor of protease enzymes had significantly increased survival rates and decreased lung viral quantities.

COVID-19 and the immunocompromised

PITTSBURGH, PA—Researchers from the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center in Pennsylvania say that immunocompromised patients are at an increased risk for severe and protracted illness following infection with SARS-CoV-2. The analysis involved 107 health care personnel and 489 immunocompromised patients who had been fully immunized with the Moderna, Pfizer-BioNTech or the Johnson & Johnson vaccine.